538P - Relationship between pretreatment levels of circulating DNA, circulating tumor cells, CEA, CA19.9 and tumor burden on CT scan in patients treated f...

Date 09 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Colon and Rectal Cancer
Gastrointestinal Cancers
Staging procedures (clinical staging)
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Melanie Hassine
Citation Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393
Authors M. Hassine1, C. Savoye-Collet2, D. Sefrioui1, L. Beaussire3, A. Gillibert4, A. Gangloff1, N. Sarafan-Vasseur3, P. Michel1, F. Di Fiore1
  • 1Gastroenterology, CHU Hôpitaux de Rouen-Charles Nicolle, 76031 - Rouen/FR
  • 2Radiology, Rouen University Hospital, 76000 - rouen/FR
  • 3Institute For Biomedical Research And Innovation, Inserm U1245, University of Rouen, 76000 - rouen/FR
  • 4Biostatistics, Rouen university hospital, 76000 - rouen/FR



Circulating DNA has been reported as prognostic in metastatic colorectal cancer (mCRC) but its correlation with tumor burden has never been clearly established. The aim was to evaluate the correlation between pretreatment levels of circulating tumor DNA (ctDNA), cell-free-DNA (cfDNA), circulating tumor cells (CTC), CEA, CA19.9 with tumor characteristics on CT scan.


It was a retrospective analysis from a prospective trial on circulating markers (ctDNA, cfDNA, CTC, CEA, CA19.9) at baseline in mCRC patients (NCT01212510). CT scans were centrally reviewed to assess 3 tumor parameters: the diameter using RECIST version 1.1, the total tumor length (TTL) defined as the sum of diameter of all visible lesions, and the volume (Vol) of the main lesion. Relationship between circulating markers and CT scan were analysed as well as progression-free survival (PFS) and overall survival (OS) and prognostic factors using Cox models.


A total of 83 mCRC patients were included. Median baseline ctDNA, cfDNA, CEA, CA19.9 and CTC were 21 (0.12-74) %, 36 (6-2275) ng/mL, 75 (2-64051) ng/ml, 90 (4-70900) UI/mL, and 7 (1-194)/mL, respectively. For CT scan, median value was 81 (11-310) mm for RECIST, 196 (14-1906) mm for TTL and 65 (2-783) mm3for Vol. There was a significant correlation between RECIST and CEA (p = 0.0005), CA19.9 (p = 0.007), cfDNA (p 


Circulating makers and tumor burden on CT scan were correlated and prognostic. Interventional studies are needed to evaluate the usefulness of circulating makers in decision making.

Clinical trial identification


Legal entity responsible for the study

Rouen University Hospital


Merck, Roche and Amgen


All authors have declared no conflicts of interest.